MedTrace Logo

Oxidative Stress and Endothelial Function in Pregnancy Complications

NCT02603913 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 330

Last updated 2016-10-31

No results posted yet for this study

Summary

Pregnancy complications like pre-eclampsia (PE), pregnancy induced hypertension (PIH), intra-uterine growth restriction (IUGR) and preterm labor (PTL), (i.e. the major part of complications in pregnancy) are related to an impaired endothelial function. Endothelial dysfunction accounts for altered vascular reactivity, activation of the coagulation cascade and loss of vascular integrity. Nitric oxide (NO), a free radical molecule derived from L-Arginine by NOS (Nitric Oxide Synthase), is an endogenous endothelium-derived relaxing factor influencing endothelial function. In the placental circulation, endothelial release of NO dilates the fetal placental vascular bed and thus ensures feto-maternal exchange. The impaired endothelial function in pregnancy complications originates from production of inflammatory and cytotoxic factors by the ischemic placenta and results in oxidative stress and an altered bioavailability of NO. Measurement of endothelial function using peripheral artery tonometry and determination of ROS (reactive oxygen species) and RNS (reactive nitrogen species) using Electron Paramagnetic Resonance (EPR) gives an idea of the oxidative stress that took place and the degree of endothelial dysfunction that occurred during pregnancy.

Conditions

  • Pregnancy Complications
  • Endothelial Dysfunction

Sponsors & Collaborators

  • University Hospital, Antwerp

    collaborator OTHER

  • Ziekenhuis Oost-Limburg

    collaborator OTHER

  • Maastricht University Medical Center

    collaborator OTHER

  • Erasmus Medical Center

    collaborator OTHER

  • Universiteit Antwerpen

    lead OTHER

Principal Investigators

  • Dominique AM Mannaerts, MD · Universiteit Antwerpen

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2019-01-31
Completion
2019-01-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02603913 on ClinicalTrials.gov